{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Leukocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Neutropenia/Granulocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Platelets"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Ascites (Non-Malignant)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Febrile Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Pain Pulmonary/Upper Respiratory-Chest/Thorax NOS"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Pleural Effusion (Non-Malignant)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Number of participants with laboratory and non-laboratory toxicities possibly related to study drug, which were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. Grades range from 0 (none) to 5 (death). Grade 3 is severe and Grade 4 is life-threatening.\n\nNOS = Not otherwise specified.","groups":[{"description":"Pemetrexed 500 mg/m2 intravenous (IV) every 21 days for 6 cycles","id":"OG000","title":"Pemetrexed"}],"paramType":"NUMBER","populationDescription":"Patients who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"baseline, up to 18 weeks","title":"Number of Participants With Common Toxicity Criteria - National Cancer Institute Grade 3 and Grade 4 Toxicities","type":"SECONDARY","unitOfMeasure":"participants"}